Table II.
Univariate logistic regression analysis of gene expression and clinicopathologic characteristics.
| Characteristics | N | Odds ratio (95% CI) | P-value |
|---|---|---|---|
| T stage, T3/T4 vs. T1/T2 | 1,062 | 0.97 (0.70-1.35) | 0.868 |
| N stage, N1/N2/N3 vs. N0 | 1,046 | 0.93 (0.73-1.18) | 0.535 |
| M stage, M1 vs. M0 | 909 | 0.65 (0.25-1.58) | 0.346 |
| Pathologic stage, III/IV vs. I/II | 1,042 | 0.86 (0.65-1.14) | 0.297 |
| PR status, positive vs. negative | 1,012 | 0.67 (0.52-0.87) | 0.003 |
| ER status, positive vs. negative | 1,015 | 0.43 (0.31-0.58) | <0.001 |
| HER2 status, positive vs. negative | 705 | 0.58 (0.41-0.84) | 0.004 |
| Histological type, infiltrating lobular carcinoma vs. infiltrating ductal carcinoma | 959 | 1.68 (1.23-2.31) | 0.001 |
| TP53 status, Mut vs. WT | 956 | 1.06 (0.82-1.39) | 0.644 |
| PIK3CA status, Mut vs. WT | 956 | 1.11 (0.85-1.46) | 0.441 |
CI, confidence interval; PR, progesterone receptor; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; WT, wild-type; Mut, mutated; TP53, tumor protein 53; PIK3CA, phosphotidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α.